<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690220</url>
  </required_header>
  <id_info>
    <org_study_id>pfm15k001 TiLOOP® PRO A</org_study_id>
    <nct_id>NCT02690220</nct_id>
  </id_info>
  <brief_title>Anterior Pelvic Prolapse Reconstruction With TiLOOP® PRO A Polypropylene Mesh</brief_title>
  <official_title>National, Multicentre Post Market Surveillance Study on Anterior Pelvic Prolapse Reconstruction With a Titanium-coated Polypropylene Mesh (TiLOOP® PRO A)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pfm medical ag</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crolll Gmbh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayes GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aix Scientifics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>pfm medical ag</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the influence of anterior pelvic prolapse
      reconstruction with a titanized polypropylene mesh on patients quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentre, non-randomized, observational clinical investigation will be performed to
      obtain usability and postmarket information on the TiLOOP® pelvic floor reconstruction meshes
      and in particular to obtain the improvement of patients' quality of life.

      It is expected that the patient's quality of life is meliorated after implantation of a
      TiLOOP® PRO A mesh. To verify this, it will be shown that by means of a validated
      questionnaire the subjective quality of life after 12 months is significantly better than
      before implantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">July 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>By means of a validated questionnaire it will be shown whether the subjective quality of life after 12 months is significantly better than before implantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>The evaluation of changes in quality of life assessed by the P-QoL 6 months after implantation of the TiLOOP® PRO A surgical mesh compared to before implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>6 weeks, 6 and 12 months</time_frame>
    <description>Assessment and analysis of all [serious] adverse events ([S]AEs) during the first 12 months after implantation along with a contextual placement of safety data based on current literature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility Check of Mesh implantation</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate mesh implantation, information about the duration of the procedure (minutes from cut to stitches) and the operability of the application set (easy, suitable, difficult, no set used) will be collected during the surgery. Taking together, this information will encapsulate the feasibility of the mesh implantation descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of complications and concomitant procedures</measure>
    <time_frame>1 day</time_frame>
    <description>Counting the number of intraoperative complications (e. g. lesion of the bladder, the urethra or the intestines) and concomitant procedures (e. g. hysterectomy, colporrhaphy, vaginal sacrospinal fixation) procedure-related adverse events as assessed by CTCAE v4.0 and common concomitant procedures will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Cystocele</condition>
  <condition>Uterine Prolapse</condition>
  <arm_group>
    <arm_group_label>surgical mesh implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally. Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TiLOOP® PRO Plus A</intervention_name>
    <description>The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.</description>
    <arm_group_label>surgical mesh implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Existence of a cystocele. Women with a symptomatic genital descensus: at least stage
             II (ICS-classification according POP-Q system). This applies to primary as well as
             recurrent intervention.

          2. Patient is mentally able to understand the nature, aims, or possible consequences of
             the clinical investigation.

          3. Patient information has been handed out and written consent is at hand.

          4. Patient has attained full age (18 years or older).

        Exclusion Criteria:

          1. Unfinished family planning, pregnancy or breast-feeding mother.

          2. Known intolerance to the mesh-implants under investigation.

          3. Lack of written patients' informed consent.

          4. Lack of patient compliance regarding data collection, treatment or follow-up
             investigations in the scope of the protocol.

          5. Patients with acute (within the last 12 months) carcinoma in the pelvic area.

          6. Patients with history of radiotherapy in the pelvic area.

          7. Patients with implanted anterior pelvic floor mesh.

          8. Patient is institutionalized by court or official order (MPG §20.3).

          9. Participation in another interventional clinical investigation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Fünfgeld, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik Tettnang GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik Tettnang GmbH</name>
      <address>
        <city>Tettnang</city>
        <state>Baden-Württemberg</state>
        <zip>88069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oberlausitzer Bergland gemeinnützige GmbH</name>
      <address>
        <city>Zittau</city>
        <state>Sachsen</state>
        <zip>02763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Amalie-Sieveking-Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Cadenbach-Blome T, Grebe M, Mengel M, Pauli F, Greser A, Fünfgeld C. Significant Improvement in Quality of Life, Positive Effect on Sexuality, Lasting Reconstructive Result and Low Rate of Complications Following Cystocele Correction Using a Lightweight, Large-Pore, Titanised Polypropylene Mesh: Final Results of a National, Multicentre Observational Study. Geburtshilfe Frauenheilkd. 2019 Sep;79(9):959-968. doi: 10.1055/a-0984-6614. Epub 2019 Sep 11.</citation>
    <PMID>31523096</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>polypropylene mesh</keyword>
  <keyword>prolapse</keyword>
  <keyword>cystocele</keyword>
  <keyword>surgical mesh</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystocele</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

